EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of K18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2

Gary Ewart iD, Michael Bobardt, Bo Hjorth Bentzen, Yannan Yan, Audrey Thomson, Klaus Klumpp, Stephen Becker, Mette M Rosenkilde, Michelle Miller, Philippe Gallay

PLOS Pathogens · 2023

DOI: 10.1371/journal.ppat.1011328 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Gary Ewart und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biotron Limited, North Ryde, New South Wales, Australia. Hauptthemen laut MEDLINE: COVID-19, Hepatitis C, Chronic. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotron Limited, HORIZON EUROPE European Research Council, Lundbeck Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Coronavirus envelope (E) protein is a small structural protein with ion channel activity that plays an important role in virus assembly, budding, immunopathogenesis and disease severity. The viroporin E is also located in Golgi and ER membranes of infected cells and is associated with inflammasome activation and immune dysregulation. Here we evaluated in vitro antiviral activity, mechanism of action and in vivo efficacy of BIT225 for the treatment of SARS-CoV-2 infection. BIT225 showed broad-spectrum direct-acting antiviral activity against SARS-CoV-2 in Calu3 and Vero cells with similar potency across 6 different virus strains. BIT225 inhibited ion channel activity of E protein but did not inhibit endogenous currents or calcium-induced ion channel activity of TMEM16A in Xenopus oocytes. BIT225 administered by oral gavage for 12 days starting 12 hours before infection completely prevented body weight loss and mortality in SARS-CoV-2 infected K18 mice (100% survival, n = 12), while all vehicle-dosed animals reached a mortality endpoint by Day 9 across two studies (n = 12). When treatment started at 24 hours after infection, body weight loss, and mortality were also prevented (100% survival, n = 5), while 4 of 5 mice maintained and increased body weight and survived when treatment started 48 hours after infection. Treatment efficacy was dependent on BIT225 dose and was associated with significant reductions in lung viral load (3.5 log 10 ), virus titer (4000 pfu/ml) and lung and serum cytokine levels. These results validate viroporin E as a viable antiviral target and support the clinical study of BIT225 for treatment and prophylaxis of SARS-CoV-2 infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Hepatitis C, ChronicChlorocebus aethiopsMiceAnimalsAntiviral AgentsVero CellsSARS-CoV-2Mice, TransgenicViroporin ProteinsTranscription FactorsPatient AcuityWeight LossIon ChannelsDisease Models, AnimalGuanidinesPyrazolesgamma-GlobulinsMelphalan

Substanzen

Antiviral AgentsViroporin ProteinsTranscription FactorsIon ChannelsN-(5-(1-methyl-1H-pyrazol-4-yl)-napthalene-2-carbonyl)guanidineGuanidinesPyrazolesK-18 conjugategamma-GlobulinsMelphalan

Autor:innen und Institutionen

  • Biotron Limited, North Ryde, New South Wales, Australia.
  • The Scripps Institute, Immunology and Microbiology, La Jolla, California, United States of America.
  • University of Copenhagen, Department of Biomedical Sciences, Copenhagen, Denmark.

ORCID-Profile: Gary Ewart

Förderung

  • Biotron Limited
  • HORIZON EUROPE European Research Council
  • Lundbeck Foundation
  • Novo Nordisk Fonden

Zitieren

APA

Ewart, G., Bobardt, M., Bentzen, B. H., Yan, Y., Thomson, A., Klumpp, K., Becker, S., Rosenkilde, M. M., Miller, M., & Gallay, P. (2023). Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of K18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011328

Vancouver

Ewart G, Bobardt M, Bentzen BH, Yan Y, Thomson A, Klumpp K, et al. Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of K18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011328

BibTeX
@article{Ewart2023,
  author = {Ewart, Gary and Bobardt, Michael and Bentzen, Bo Hjorth and Yan, Yannan and Thomson, Audrey and Klumpp, Klaus and Becker, Stephen and Rosenkilde, Mette M and Miller, Michelle and Gallay, Philippe},
  title = {Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of K18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2},
  journal = {PLOS Pathogens},
  year = {2023},
  doi = {10.1371/journal.ppat.1011328}
}
Kostenlos starten →